Amgen’s Nplate Has First Mandatory Patient Registration Under REMS
Executive Summary
The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients
You may also be interested in...
Finally, A REMS FDA Could Live With
"It took us three months" to negotiate with FDA on the fine points of the REMS and make the refinements required to finalize the document, Amgen safety exec Rekha Garg told the recent Post-Approval Summit at Harvard.
REMS For Opioids: Industry Considering Prescriber, Dispenser Certification
Drug makers have agreed on communications, education components of strategy.
Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS
After a three-day, three-drug advisory committee in November, the last sponsor standing - or at least the last to get a "complete response" letter from FDA - may be in the best position to move forward with its complicated skin and skin structure infections antibiotic